This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CStone Pharmaceuticals Grants Exclusive Promotion Rights for Tumor Drug in China to Jiangsu Hengrui Medicine MT
Voluntary Announcement - CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals Co., Ltd Enter into an Exclusive Promotion Agreement of AYVAKIT® (avapritinib tablets) in Mainland China CI
CStone Pharmaceuticals Announces Change of Joint Company Secretary CI
CStone Gets Green Light for Local Manufacturing of AYVAKIT in China MT
CStone Pharma Presents Cancer Drug Study Data at US Oncology Society Meeting MT
CStone. Pharmaceuticals Announces Presentation of Latest First-In-Human Data for CS5001 (RoR1 ADC) at ASCO 2024 CI
European Regulators Recommend CStone Pharmaceuticals’ Sugemalimab for Approval, Shares Up 13% MT
Cstone Pharmaceuticals Announces CHMP of the European Medicine Agency Recommends Approval of Cejemly (Sugemalimab, Anti-Pd-L1) as First-Line Treatment for NSCLC CI
CStone Pharmaceuticals to License Anti-Cancer Drug in 19 European Countries MT
CStone Pharmaceuticals Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website CI
Cstone Pharmaceuticals To Present Cancer Results at 2024 ASCO MT
Non-Executive Director Increases Shareholding in CStone Pharma; Shares Surge 25% MT
Cstone Pharmaceuticals’ CEO Boosts Stakeholding MT
Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5% MT
CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor MT
CStone Announces the Availability of RET Inhibitor GAVRETO® Manufacturing Localization Application by Center for Drug Evalence of China NMPA CI
Cstone Pharmaceuticals Cancer Drug Gets Supplemental Biologics License Application Approved MT
CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer CI
CStone Pharmaceuticals Booted From Hong Kong Stock Connect; Shares Plunge 25% MT
CStone Pharmaceuticals Arm to Sell Ivosidenib Business for $50 Million MT
The Servier Group agreed to acquire CStone Pharmaceuticals, Exclusive rights to TIBSOVO® in Greater China and Singapore from CStone Pharmaceuticals for $44 million. CI
China Includes CStone's Gastrointestinal Stromal Tumor Treatment in National Reimbursement List; Shares Jump 6% MT
China Approves CStone Pharma's Treatment for Esophageal Squamous Cell Carcinoma; Shares Soar 21% MT
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma CI
Chart CStone Pharmaceuticals
More charts
CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in domestic market.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
1.096 CNY
Average target price
2.698 CNY
Spread / Average Target
  1. Stock Market
  2. Equities
  3. 2616 Stock
  4. News CStone Pharmaceuticals
  5. CStone Gets Green Light for Local Manufacturing of AYVAKIT in China